Vitro Biopharma, Inc. (VTRO)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Vitro Biopharma, Inc. Stock (VTRO) Company Profile

Vitro Biopharma, Inc.

Healthcare (1074)

Biotechnology (600)

(720) 859-4120

4621 TECHNOLOGY DRIVE, GOLDEN

Nächster Verdiensttermin

Neueste SEC-Einreichungen

VTRO's Discussions on Twitter

Compare VTRO vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VTRO Vitro Biopharma, Inc.	0.00	0	1.65M	-5.91M	-3.03M	-0.1707
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Vitro Biopharma, Inc. Aktie (VTRO) Neueste Nachrichten

Finanzdaten der Vitro Biopharma, Inc.-Aktie (VTRO)

Vitro Biopharma, Inc. (VTRO)

Vitro Biopharma, Inc. Stock (VTRO) Company Profile

Compare VTRO vs VRTX, REGN, ARGX, MRNA, RVMD

Vitro Biopharma, Inc. Aktie (VTRO) Neueste Nachrichten

Loss of CD44 re-educates pancreatic cancer-associated fibroblasts modulating their fibrotic and immunosuppressive functions - Nature

J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout - Fierce Biotech

World In Vitro Transcription Enzyme MixesMarket Analysis, Forecast, Size, Trends and Insights - IndexBox

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits - Business Wire

Legend surges on early data for ‘in vivo’ lymphoma cell therapy - BioPharma Dive

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives - The Manila Times

How GT Biopharma is using AI to shrink drug timelines and costs - Stock Titan

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104Important Step in RHB-204 Development for MAP-related Crohn's Disease - PR Newswire

Boston meeting will spotlight Cue Biopharma's new autoimmune drug data - Stock Titan

VTRO (Vitro Biopharma) PB Ratio : 0.00 (As of Mar. 26, 2026) - GuruFocus

These 18 french biotech startups could shape tomorrow’s medicine - Labiotech.eu

Cue Biopharma to present new in vitro data for CUE-401 - TipRanks

Cue Biopharma unveils in vitro data for CUE-401 in autoimmune disease research - Traders Union

Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - GlobeNewswire

The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant

Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool

KDDF: advancing Korea’s oncology sector globally - Nature

How new approach methodologies are reshaping drug discovery - McKinsey & Company

Early bits of in vivo CAR-T human data emerge from biotech trials in China - Endpoints News

Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - CRISPR Medicine News

Vitro Biopharma Launches New Products to Advance Breast Cancer Treatment - ACCESS Newswire

Vitro Biopharma Announces Early 2016 Results: Increased Revenue and Expansion Activities to Fuel Growth - ACCESS Newswire

The 16th international oncolytic virotherapy conference: from in vitro to clinical studies, novel approaches in cancer therapy meeting report - Frontiers

Vitro Biopharma | CORRESP: CORRESP - Moomoo

Closing the women’s health gap: Biopharma’s untapped opportunity - McKinsey & Company

In Vitro Diagnostics (IVD) Market Size to Surpass USD 157.56 Billion by 2034 - BioSpace

Press Release Service: Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia - CRISPR Medicine News

Vitro Biopharma(VTRO) Stock Options Chain | Quotes & News - Moomoo

Top 5 In-Vitro Diagnostics [IVD] Companies - Fortune Business Insights

In Vivo CRO Market Size to Reach USD 13.74 Billion By 2033 - biospace.com

A biotech working on a new approach to IVF raises $33M in fresh funding - BioPharma Dive

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications - BioSpace

Asgard Therapeutics Snags €30M to Develop In Vivo Direct Cell Reprogramming Technologies for Cancer - BioInformant

Vitro Biopharma Company Profile & Introduction - Moomoo

EDGAR Filing Documents for 0001493152-24-004779 - SEC.gov

Vitro Biopharma(VTRO) Stock Price Today | Quotes & News - Moomoo

Matinas BioPharma Demonstrates in vivo Biological Activity - GlobeNewswire

Vitro Biopharma, Inc. announced a financing transaction - marketscreener.com

Vitro Biopharma, Inc. (VTRO) Stock Live Price, Chart & News - CoinCodex

Experience real-time quotes, in-depth charts, and analyst ratings - webull.com

VTRO IPO NewsStem cell biotech Vitro Biopharma sets terms for $10 million IPO - renaissancecapital.com

The Next Normal – The future of biotech: AI-driven drug discovery - McKinsey & Company

FUJIFILM Irvine Scientific PRIME-XV Stem FreezIS DMSO-Free Cryopreservation Medium to be Used in FDA-Authorized Clinical Trial - Business Wire

Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care - Business Wire

Vitro Biopharma, Inc. has filed an IPO in the amount of $17.25 million. - marketscreener.com

Biotech - McKinsey & Company

Business of Biotechniques 2022 - BioTechniques

Developing A Robust In Vitro Intestinal Model For Preclinical Candidate Screening Of GI Toxicity - Pharmaceutical Online

FinancialContentAytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells - FinancialContent

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19 - BioInformant

DVC Stem: Stem Cell Therapy Clinic in the Cayman Islands - BioInformant

Finanzdaten der Vitro Biopharma, Inc.-Aktie (VTRO)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie VTRO